Adakveo (crizanlizumab)
$1,999.00Adakveo (crizanlizumab) is a medication used to prevent painful crises in patients with sickle cell disease aged 16 years and older.
It is the first targeted therapy approved for sickle cell disease.
Showing 1–16 of 270 results
Adakveo (crizanlizumab) is a medication used to prevent painful crises in patients with sickle cell disease aged 16 years and older.
It is the first targeted therapy approved for sickle cell disease.
Adbry tralokinumab-ldrm represents a promising new treatment option for patients with moderate to severe asthma. By targeting IL-13,
One of the key advantages of tralokinumab-ldrm is its targeted mechanism of action.
Aduhelm represents a significant step forward in the treatment of Alzheimer’s disease, with its advanced effects and benefits making it an exciting development in the field of Alzheimer’s research.
The drug offers hope to millions of people worldwide suffering from Alzheimer’s disease,
Aduhelm (aducanumab-avwa) is a prescription medicine used to treat people with mild cognitive impairment or mild dementia,. It is the first novel therapy approved for Alzheimer’s disease since 2003.
Ajovy (fremanezumab-vfrm) is a promising new drug for the prophylactic treatment of migraines in adults.
Its advanced effects are due to its unique mechanism of action, which targets the underlying cause of migraines by blocking the release of CGRP. 1 prefilled syringe of 225 mg/1.5mL
Skyrizi (risankizumab) is a medication used to treat adults with Plaque Psoriasis and Psoriatic Arthritis.
Ammonaps (sodium phenylbutyrate) is a prescription medication that is used for the treatment of urea cycle disorders. By reducing the levels of nitrogen in the blood and promoting the excretion of excess nitrogen,
Ammonaps can improve cognitive function and liver function in patients with these conditions. 250 tablets of 500 mg
Ammonaps (sodium phenylbutyrate) is a medication used for the treatment of patients who have urea cycle disorders.
Neurologists sometimes prescribe Ammonaps for off-label treatment of people suffering from ALS.
Amondys 45 (casimersen) is an FDA-approved medication that can potentially improve the quality of life of DMD patients who have a specific mutation in exon 45 of the dystrophin gene.
Amondys 45 works by inducing exon skipping and promoting the production of truncated dystrophin, which can partially restore muscle function in affected individuals.
Amondys 45 (casimersen) is a medication used for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.
4 vials
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) is a medication used for the treatment of patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
This is the first approved antidote for apixaban- or rivaroxaban-treated patients with uncontrolled bleeds.
We help people everywhere in the world access the latest medicines not available in their countries. We are an independent medicines intermediary platform and international pharmacy sourcing each medicine for named patient compassionate use and are overseeing every aspect of the shipping, customs and delivery.
Don’t miss our future updates! Get Subscribed Today!